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Hypokalaemia is a common clinical disorder, the cause of
which can usually be determined by the patient’s clinical
history. Gitelman syndrome is an inherited tubulopathy that
must be considered in some settings of hypokalaemia. We
present the case of a 60-year-old male patient referred to
our nephrology department for persistent hypokalaemia.
Clinical history was positive for symptoms of orthostatic
hypotension and polyuria. There was no history of drugs
consumption other than potassium supplements.
Complementary evaluation revealed hypokalaemia
(2.15 mmol/l), hypomagnesaemia (0.29 mmol/l), metabolic
alkalosis (pH 7.535, bicarbonate 34.1 mmol/l),
hypereninaemia (281.7 U/ml), increased chloride
(160 mmol/l) and sodium (126 mmol/l) urinary excretion
and reduced urinary calcium excretion (0.73 mmol/l). Renal
function, remainder serum and urinary ionogram, and renal
ultrasound were normal. A diagnosis of Gitelman syndrome
was established. We reinforced oral supplementation with
potassium chloride and magnesium sulfate. Serum
potassium stabilised around 3 mmol/l. The aim of our
article is to remind Gitelman syndrome in the differential
diagnosis of persistent hypokalaemia.
BACKGROUND
Hypokalaemia is a frequent electrolyte disturbance,
particularly in hospitalised patients. In most cases of
chronic hypokalaemia, the cause is straightforward,
usually resulting from unreplenished gastrointestinal
or urinary losses. Gitelman syndrome (GS) is an auto-
somal recessive salt-losing renal tubulopathy that
causes hypokalaemia and metabolic alkalosis.1
CASE PRESENTATION
We present the case of a 60-year-old Portuguese
Caucasian male with persistent hypokalaemia,
referred to our nephrology department. This condi-
tion had ﬁrst been found at the age of 55 during
hospitalisation for community-acquired pneumonia,
and he had been irregularly taking oral magnesium
and potassium supplements ever since.
Anamnesis was positive, with a long time history
of symptoms of orthostatic hypotension and
records of systolic blood pressure always below
120 mm Hg. He referred polyuria and nycturia
with no other urinary tract symptoms. His medical
history was not signiﬁcant. Other than the above-
mentioned supplements, he denied any drug
intake. His family history was negative.
On physical examination he had a blood pressure
of 110/70 mm Hg and regular pulse frequency of
80/min, normal hydration and colouration of skin
and mucosa. Cardiopulmonary examination was
normal with no signs of peripheral oedema. The
remaining physical examination was normal.
On gas analysis, he presented a metabolic alkalosis
(pH 7.535; pCO2 40 mmHg; HCO3 34.1 mmol/l).
Biochemical analysis revealed hypokalaemia
(2.46 mmol/l), hypomagnesaemia (0.38 mmol/l) and
hypochloraemia (95 mmol/l). Serum creatinine
(62 μmol/l), urea (6.3 mmol/l) and remainder ionogram
were normal. Further investigation revealed elevated
plasma-active renin (281.7 μU/ml; NR 4.4–46.1),
normal aldosteronaemia (16.7 ng/ml in orthostatism;
NR 4–31), hypocalciuria (0.73 mmol/l; NR 2.5–7.5)
and increased urinary excretion of sodium
(126.5 mmol/l; NR 20–110) and chloride (160 mmol/
l; NR 55–125). Estimated glomerular ﬁltrate rate
(MDRD) was 115 ml/min/1.73 m2 and potassium
transtubular gradient was 11.6. Electrocardiogram
showed normal sinus rhythm with a rate of 74/min.
Renal ultrasound, and renal and adrenal CT revealed
normal kidneys.
Based on the association of hypomagnesaemia,
hypokalaemia, metabolic alkalosis, hypocalciuria
and low-normal blood pressure, the diagnosis of
GS was established.
TREATMENT
The patient began oral supplementation with mag-
nesium aspartate/potassium aspartate 250/250 mg
four times a day (qid), magnesium aspartate
1229.6 mg once a day (qd) and potassium chloride
600 mg twice daily (bid) and he was encouraged to
maintain a high-sodium and high-potassium diet.
A therapeutic trial with spironolactone was inter-
rupted due to mammal pain.
OUTCOME AND FOLLOW-UP
Two months later he was asymptomatic with serum
potassium 2.9 mmol/l and magnesium 0.52 mmol/l.
We reinforced ion supplementation. For profes-
sional reasons, the patient went abroad on a per-
manent basis and the follow-up was lost.
DISCUSSION
Chronic hypokalaemia is a common clinical problem
with potentially life-threatening manifestations.
Our patient had a long time history of symptom-
atic hypotension and persistent hypokalaemia with
metabolic alkalosis and hypomagnesaemia. Vomiting
and diuretic abuse, the two major diagnoses in this
setting, were excluded by measuring a high urinary
chloride excretion and by a negative history of diur-
etic use, respectively. The remaining differential diag-
noses were the genetic disorders of Gitelman and
Bartter syndromes. Bartter syndrome was improbable
because it usually has an earlier onset and a more
severe phenotype, urinary calcium excretion is often
increased and the magnesaemia is normal or mildly
reduced.
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Rare disease
Thus, our ﬁnal diagnosis was GS (MIM #263 800), an auto-
somal recessive salt-losing renal tubulopathy. In the vast majority
of cases, disease is due to inactivating mutations in the gene
that encodes the renal thiazide-sensitive sodium-chloride cotran-
sporter (NCC) present in the epithelial cells of the renal distal
convoluted tubule (DCT).2 It is characterised by hypomagnes-
aemia, hypocalciuria and secondary hyperaldosteronism that
induce hypokalaemia and metabolic alkalosis. Clinical manifes-
tations are similar to the prolonged administration of thiazide
diuretics.3
GS is often not diagnosed until late childhood or even adult-
hood. Cramps, paresthesias and fatigue frequently occur. Most
patients report recurrent periods of carpopedal spasms during
vomiting, diarrhoea or fever. Chondrocalcinosis occurs later in
life, and maybe the consequence of hypomagnesaemia.4 Blood
pressure is lower in the general population.
The diagnosis of GS is based on the clinical symptoms and
biochemical abnormalities, which include hypomagnesaemia,
hypokalaemia, metabolic alkalosis and hypocalciuria. GS
patients have a blunted natriuretic response to thiazide, but a
prompt natriuresis after furosemide, indicating that the defect is
located at the level of the distal tubule. DNA mutation analysis
of the gene responsible for GS may conﬁrm the diagnosis.1 4
Most asymptomatic patients remain untreated and undergo
ambulatory monitoring with low frequency. Progression to renal
insufﬁciency is extremely rare.5
Concerning treatment, supplementation with magnesium is
indicated, along with a high sodium and high potassium diet. If
symptomatic hypokalaemia is not corrected, it can be the asso-
ciated drugs that antagonise aldosterone activity or block the
sodium channel ENaC in the collecting duct. An option is the
combination of amiloride, spironolactone or eplerenone with
potassium chloride.1
Learning points
▸ Remember Gitelman syndrome in situations of unexplained
hypokalaemia, hypomagnesaemia and metabolic alkalosis.
▸ Gitelman syndrome is an autosomal recessive salt-losing
renal tubulopathy.
▸ Clinical manifestations of Gitelman syndrome mimetise
prolonged administration of thiazide diuretics
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